Q-Line Biotech Limited (NSE:QLINE)

Q-Line Biotech Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 13, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.92	0.92	0.88	0.60	0.58	0.43
Debt / EBITDA Ratio	2.16	2.16	2.14	2.51	2.11	0.58
Net Debt / Equity Ratio	0.61	0.61	0.63	0.41	-0.13	-0.10
Net Debt / EBITDA Ratio	1.43	1.43	1.54	1.73	-0.47	-0.14
Net Debt / FCF Ratio	-7.63	-7.63	-2.25	-0.92	12.61	-
Asset Turnover	0.67	0.67	0.79	0.69	0.82	2.09
Inventory Turnover	1.46	1.46	1.52	1.26	2.18	4.29
Quick Ratio	1.02	1.02	0.79	0.40	1.14	1.24
Current Ratio	1.64	1.64	1.48	1.42	1.63	2.20
Return on Equity (ROE)	25.55%	25.55%	10.92%	23.82%	27.99%	73.78%
Return on Assets (ROA)	11.76%	11.76%	11.10%	7.35%	9.23%	31.45%
Return on Invested Capital (ROIC)	20.80%	20.80%	13.17%	16.22%	25.62%	70.15%
Return on Capital Employed (ROCE)	27.40%	27.40%	25.50%	17.50%	22.80%	65.50%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 13, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Buyback Yield / Dilution	-6.78%	-1.70%	-	-	-5.00%	-0.00%

Data Source: S&P Global Market Intelligence Last updated: Sep 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 14, 2026

Data Sources Report a data error